Metallosis and Adverse Reaction to Metal Debris: Hip Implant Treatment in Birmingham
Metallosis is a complication of metal-on-metal hip replacements, in which microscopic metal particles and ions released by the implant cause progressive soft tissue damage, fluid collections, and bone loss. Many patients who received metal-on-metal hip replacements between 2003 and 2012 are now presenting with symptoms requiring specialist revision surgery. Mr Shakir Hussain is one of the UK's highest-volume hip resurfacing surgeons, with specific expertise in the diagnosis, monitoring, and revision of metal-on-metal hip implants at the Royal Orthopaedic Hospital Birmingham.
What is metallosis and adverse reaction to metal debris (ARMD)?
Metallosis is the accumulation of metallic wear debris in the soft tissues around a hip implant. When cobalt-chromium alloy bearing surfaces articulate against each other in metal-on-metal hip replacements, they release both microscopic particles and dissolved metal ions. The body's inflammatory response to this debris can cause progressive soft tissue destruction, fluid collections (pseudotumours), bone loss, and, in severe cases, systemic toxic effects from absorbed cobalt and chromium.
Historical context: the large-head metal-on-metal era
Between approximately 2000 and 2012, large-head metal-on-metal total hip replacements were widely implanted, particularly in younger and more active patients, because surgeons believed the larger head diameter would reduce dislocation risk and the metal-on-metal bearing would provide superior wear performance to conventional polyethylene. In the UK alone, an estimated 50,000 patients received these implants. However, by 2010 it became clear that many large-head MoM devices were generating unexpectedly high levels of cobalt and chromium ion release, causing adverse soft-tissue reactions in a significant proportion of patients.
The MHRA issued a medical device alert in 2010 and updated safety guidance in 2012. The DePuy ASR hip system (both resurfacing and total hip replacement variants) was recalled by the manufacturer after data showed revision rates substantially above acceptable thresholds. Other devices, including some versions of the Biomet M2a-Magnum, were also subject to safety alerts. The DePuy ASR recall is one of the largest medical device recalls in history and affected over 90,000 patients worldwide.
Distinguishing large-head MoM THA from hip resurfacing
It is important to distinguish between three categories of metal-bearing hip implant, which have different risk profiles:
- Large-head metal-on-metal total hip replacement. The primary source of the metallosis crisis. These devices couple a large (greater than 36 mm) cobalt-chromium femoral head with a cobalt-chromium acetabular cup. The large head-to-neck ratio concentrates edge loading at the cup rim if the cup is positioned suboptimally, dramatically increasing metal ion release. Many of these devices have been recalled or withdrawn.
- Hip resurfacing with metal-on-metal bearings (Birmingham Hip Resurfacing). Hip resurfacing has a fundamentally different tribological profile. The femoral component is a cap placed over the patient's own femoral head rather than a replacement. BHR has a substantially better long-term track record than the large-head THA devices that caused most metallosis problems, with 20-year data from large registry series showing acceptable revision rates in appropriately selected male patients. The BHR system specifically (Smith and Nephew) has registry data supporting its continued use in selected patients. However, all patients with BHR implants require the same MHRA-recommended annual metal ion monitoring as other MoM implants.
- Ceramic alternatives (ReCerf and others). Ceramic-on-ceramic hip resurfacing (ReCerf) and ceramic-on-ceramic total hip replacement eliminate all metal ion concerns. Mr Hussain offers both BHR and ReCerf, selecting the appropriate option based on patient sex, bone quality, and any pre-existing metal sensitivity. Women are preferentially offered ceramic resurfacing because female sex is associated with higher ion levels and greater susceptibility to ARMD.
The ARMD spectrum
Adverse reaction to metal debris encompasses a spectrum of severity. At one end, patients have mildly elevated ion levels on blood testing but no symptoms and no soft-tissue changes on imaging. At the other, severe ALVAL (aseptic lymphocyte-dominated vasculitis-associated lesion) involves necrosis of the hip abductor muscles, large destructive pseudotumours, and significant bone loss. The intermediate spectrum includes periarticular fluid collections (cystic pseudotumours), mixed solid-cystic pseudotumours, and expanding solid pseudotumours that can compress adjacent nerves and vessels.
What are the symptoms of metallosis after hip replacement?
Groin or buttock pain that returns or persists in a patient with a known metal-on-metal hip implant is the most common symptom. A palpable swelling near the hip, elevated blood metal ion levels on routine monitoring, or systemic symptoms such as tinnitus or visual disturbance in patients with very high ion levels all require urgent specialist assessment.
Groin or buttock pain
Returning or persistent pain in the groin, buttock, or lateral hip in a patient with a known MoM implant. Pain may have been present since surgery or develop years later as wear increases with cumulative bearing cycles. Any new or worsening hip pain in a MoM patient warrants investigation.
Palpable swelling or pseudotumour
A lump felt near the hip joint, or a visibly swollen region around the groin or lateral hip. Pseudotumours can expand to considerable size before becoming clinically obvious and may compress adjacent nerves or vessels, causing referred symptoms in the thigh or leg.
Elevated blood metal ion levels
Detected on routine MHRA-recommended blood monitoring. Cobalt above 119 nmol/L or chromium above 134 nmol/L (MHRA thresholds) indicates concerning ion levels requiring further investigation with MARS MRI regardless of whether symptoms are present.
Systemic metal toxicity symptoms
In cases of very high metal ion absorption: tinnitus (ringing in the ears), blurred vision, peripheral tingling or numbness, or cognitive changes. These systemic effects require urgent assessment and are more common with very high ion levels or in patients with bilateral MoM implants doubling the total systemic ion burden.
Weakness and reduced function
Destruction of the abductor muscles (the key hip stabilisers) by metallic debris is one of the most functionally disabling aspects of advanced ARMD, causing a Trendelenburg limp and impaired single-leg stance. Abductor damage may not fully recover even after successful revision surgery, making early detection and treatment critically important.
Hip click or squeak
Some patients with MoM bearings report audible or palpable clicking that may be related to trunnion corrosion (the metal junction between the femoral head and stem taper) or edge loading of the bearing surfaces, both of which accelerate metal ion release and warrant assessment even in the absence of pain.
What causes metallosis to develop after hip replacement?
Metallosis is caused by accelerated wear or corrosion of metal-on-metal bearing surfaces. The main risk factors are cup malposition (which increases edge loading and ion release), large acetabular cup diameter, trunnion corrosion at the head-neck junction, female sex, bilateral MoM implants, and patient factors including BMI and activity level.
Not all metal-on-metal hip replacements develop metallosis at the same rate. Several factors accelerate metal ion release:
- Cup malposition (steep abduction angle). When the acetabular cup is positioned with a high abduction angle (above 50 to 55 degrees in most systems), the femoral head contacts the rim of the cup rather than the full bearing surface. This edge loading concentrates contact stress over a small area, dramatically increasing local wear and ion release. Cup malposition is the single most important modifiable risk factor.
- Large acetabular cup diameter. Larger head diameters (above 36 mm in total hip replacement, less relevant in resurfacing due to different tribology) increase the contact area and linear velocity at the bearing surface, generating more metal debris per unit time.
- Trunnion corrosion (trunnionosis). The junction between the cobalt-chromium femoral head and the titanium or cobalt-chromium stem taper is a site of crevice corrosion that releases metal ions independently of the primary bearing surface. Trunnionosis contributes to total systemic ion burden and can occur even when the bearing surfaces are performing adequately.
- Female sex. Women consistently show higher blood metal ion levels than men for a given implant system and cup size, and appear to have a lower threshold for developing ARMD at equivalent ion levels. This is one of the principal reasons ceramic alternatives are preferred in female patients considering hip resurfacing.
- Bilateral MoM implants. Patients with bilateral metal-on-metal hip replacements have double the systemic ion exposure of unilateral patients, increasing the risk and severity of systemic cobalt and chromium toxicity.
- Patient activity and BMI. Higher activity levels increase cumulative bearing cycles; higher body weight increases contact forces with each cycle. Both accelerate wear in any bearing combination, but the effect is particularly pronounced with MoM bearings because wear debris is biologically active.
How is metallosis diagnosed?
Blood metal ion testing (serum cobalt and chromium) is the essential first-line investigation for all patients with metal-on-metal hip implants. MARS MRI (Metal Artefact Reduction Sequence MRI) is the gold-standard imaging investigation for soft tissue assessment, providing detailed visualisation of fluid collections, pseudotumours, and soft tissue destruction that standard MRI cannot deliver around metal implants. X-rays assess component position and bone stock.
Blood metal ion testing
Serum cobalt and chromium levels are measured annually for all MoM hip replacement patients in line with MHRA guidance. The MHRA thresholds that trigger further investigation and mandatory MARS MRI are cobalt above 119 nmol/L (7 micrograms per litre) or chromium above 134 nmol/L (7 micrograms per litre). Ion levels above these thresholds require further investigation even in asymptomatic patients. Very high levels (above 300 to 400 nmol/L) are associated with an increased risk of systemic toxicity and require urgent multidisciplinary assessment.
MARS MRI: why standard MRI fails and MARS is needed
Standard MRI sequences are severely degraded by the magnetic susceptibility artefact produced by metal implants, rendering them unable to visualise the periprosthetic soft tissues reliably. MARS (Metal Artefact Reduction Sequence) MRI uses specific acquisition parameters, including high bandwidth, view-angle tilting, and modified pulse sequences, that dramatically suppress metal artefact and restore image quality in the region of the implant. MARS MRI can accurately depict fluid collections, pseudotumour extent and character, abductor muscle integrity, neurovascular involvement, and bone oedema or erosion. It is the investigation of choice for symptomatic MoM patients and for those with elevated ion levels above MHRA thresholds, regardless of symptom status.
The pseudotumour classification on MARS MRI distinguishes cystic (fluid-filled), solid, and mixed lesions, and grades soft tissue involvement from minimal to severe abductor destruction. This classification directly informs the urgency and complexity of surgical planning.
- X-rays assess acetabular cup position and abduction angle (identifying the malposition that drives edge loading), the presence of osteolytic lesions around the implant, and any component migration indicating loosening secondary to bone loss.
- Blood tests (CRP, ESR, WCC) help exclude concurrent periprosthetic infection, which must be carefully distinguished from ARMD, as both can present with elevated inflammatory markers and a painful hip after MoM arthroplasty. Joint aspiration may be required if infection cannot be confidently excluded.
How is metallosis and ARMD treated?
For asymptomatic patients with borderline ion levels and no MARS MRI changes, surveillance and monitoring is appropriate. For patients with symptomatic ARMD, pseudotumour, significantly elevated ions, or MARS MRI changes, revision surgery is required. The goal is removal of all metal-bearing surfaces, thorough debridement of necrotic tissue and pseudotumour, and reconstruction with ceramic bearings to eliminate further metal ion exposure.
The decision to proceed with surgery is based on the MHRA guidance, MARS MRI findings, blood ion levels, and the patient's symptoms and functional status. Mr Hussain discusses each case individually, and for complex cases with large pseudotumours or significant bone loss, multidisciplinary input from orthopaedic oncology soft tissue expertise and microbiology is sought at the Royal Orthopaedic Hospital.
Surveillance and Monitoring
Patients with mildly elevated ion levels below MHRA action thresholds, no symptoms, and no MARS MRI soft tissue changes are managed with intensified surveillance. This is not a passive approach: it involves structured regular review to detect any change that would trigger intervention at the earliest and most surgically favourable point.
- Annual serum cobalt and chromium blood testing
- MARS MRI every 1 to 2 years depending on ion trend
- Clinical review with functional assessment
- Patient education on warning symptoms requiring earlier review
- Prompt re-assessment if new symptoms develop between scheduled reviews
Revision Surgery to Non-Metal Bearing
All metal-on-metal components are removed. Thorough debridement of necrotic tissue, pseudotumour capsule, and metallic debris staining is performed. The reconstruction uses ceramic-on-ceramic or ceramic-on-HXLPE bearings to eliminate future metal ion release entirely. Where abductors are involved, soft tissue reconstruction is attempted as far as the degree of destruction permits. Cases with significant bone loss require augmented acetabular reconstruction or revision-grade femoral stems, as for any complex revision hip replacement.
- All MoM components removed including femoral head and acetabular cup
- Thorough pseudotumour debridement and necrotic tissue excision
- Ceramic-on-ceramic or ceramic-on-HXLPE reconstruction
- Soft tissue reconstruction of abductors where feasible
- Augments or cages for acetabular bone defects where required
Revision for ARMD is technically demanding because the normal soft tissue planes around the hip are often obliterated by metallic staining, necrosis, and scar tissue. At the Royal Orthopaedic Hospital Birmingham, Mr Hussain has access to specialist orthopaedic oncology soft tissue expertise for complex pseudotumour excision cases, as well as the full range of ceramic revision implants. For patients with very high ion levels causing systemic symptoms, urgent assessment by a cardiologist or neurology specialist may also be required before surgery.
What are the outcomes after revision for metallosis and ARMD?
Outcomes after revision for ARMD depend critically on the extent of soft tissue destruction before surgery. Revision performed before severe abductor muscle involvement achieves satisfactory functional outcomes in 70 to 85 per cent of cases. Earlier intervention, before extensive muscle necrosis, gives substantially better results. Successful revision to ceramic bearings eliminates further metal ion release in 100 per cent of cases.
The single most important determinant of functional outcome after ARMD revision is the integrity of the hip abductor muscles at the time of surgery. The gluteus medius and minimus muscles are the primary hip stabilisers. When they are substantially destroyed by metallic debris before revision is performed, the resulting Trendelenburg gait and functional impairment may be permanent, even in technically successful revisions with perfect implant positioning and stable fixation.
This is why the surveillance and monitoring programme is not merely a way of delaying surgery: it is the mechanism for identifying the optimal surgical window, before irreversible soft tissue destruction occurs but with sufficient certainty that surgery is necessary. Acting on MHRA ion thresholds and MARS MRI changes, even in the absence of significant pain, consistently produces better functional outcomes than waiting until symptoms become severe.
Blood metal ion levels normalise rapidly after successful revision to ceramic bearings, typically falling to within normal limits within three to six months. Systemic symptoms attributable to cobalt toxicity (tinnitus, visual disturbance, cognitive changes) generally improve after ion levels normalise, though in patients with very prolonged and very high ion exposure before revision, some neurological effects may persist.
One of the UK's highest-volume hip resurfacing surgeons
Consultant at the Royal Orthopaedic Hospital
One of Europe's largest specialist orthopaedic centres, with access to MARS MRI, specialist orthopaedic oncology soft tissue expertise for complex pseudotumour excision, dedicated microbiology and infection services, and the full range of ceramic revision implants including ceramic-on-ceramic and dual mobility constructs.
One of the UK's highest-volume hip resurfacing surgeons
Mr Hussain is recognised by the National Consultant Information Programme (NCIP) as one of the country's highest-volume hip surgeons. He performs both the Birmingham Hip Resurfacing (BHR) metal-on-metal system for appropriately selected male patients, and the ReCerf ceramic-on-ceramic resurfacing system for patients in whom metal sensitivity or ion concerns make a ceramic alternative preferable. This dual-platform approach means he can offer a resurfacing option to a wider range of patients, including women. Read about hip resurfacing at Mr Hussain's practice.
British Hip Society Travelling Fellowship at ENDO-Klinik Hamburg
Trained under Professor Thorsten Gehrke and Professor Mustafa Citak, who have specific expertise in the complex revision surgery required for failed metal-on-metal hip implants with associated bone loss and soft tissue destruction from ARMD.
Metal ion monitoring and specialist ARMD assessment
All patients with BHR implants from Mr Hussain's practice are monitored with regular blood cobalt and chromium ion testing in line with MHRA guidance, enabling early detection of any ion elevation before symptoms or tissue damage develop. Mr Hussain provides structured surveillance programmes tailored to each patient's implant type and risk profile.
Doctify Outstanding Patient Experience 2024, 2025, and 2026
Awarded in three consecutive years, recognising consistently high patient-reported outcomes and communication throughout the surgical journey, including for patients navigating the uncertainty of a metal-on-metal implant recall or safety alert.
4.98 out of 5 from verified reviews on Doctify. Outstanding Patient Experience Award 2024, 2025, and 2026.
Frequently asked questions about metallosis and metal-on-metal hip implants
For more questions about surgery, recovery, fees, and what to expect, see the full frequently asked questions page or read recent patient testimonials.